{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:25:36Z","timestamp":1792481136037,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00259-020-04815-w","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T10:02:46Z","timestamp":1587981766000},"page":"2776-2786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["FDG PET\/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1273-5835","authenticated-orcid":false,"given":"Amir","family":"Iravani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medhat M.","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Weppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roslyn","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Galligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arian","family":"Lasocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan O.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Akhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K. H.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Kee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Au-Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"4815_CR1","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1056\/NEJMc1714339","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Rollin L, Larkin J. Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377:2503\u20134. https:\/\/doi.org\/10.1056\/NEJMc1714339.","journal-title":"N Engl J Med"},{"key":"4815_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1003466.","journal-title":"N Engl J Med"},{"key":"4815_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030.","journal-title":"N Engl J Med"},{"key":"4815_CR4","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(18)30700-9.","journal-title":"Lancet Oncol"},{"key":"4815_CR5","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1910836.","journal-title":"N Engl J Med"},{"key":"4815_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u201368. https:\/\/doi.org\/10.1056\/NEJMra1703481.","journal-title":"N Engl J Med"},{"key":"4815_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13:473\u201386. https:\/\/doi.org\/10.1038\/nrclinonc.2016.58.","journal-title":"Nat Rev Clin Oncol"},{"key":"4815_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2015.00001","volume":"6","author":"CS Palmer","year":"2015","unstructured":"Palmer CS, Ostrowski M, Balderson B, Christian N, Crowe SM. Glucose metabolism regulates T cell activation, differentiation, and functions. Front Immunol. 2015;6:1. https:\/\/doi.org\/10.3389\/fimmu.2015.00001.","journal-title":"Front Immunol"},{"key":"4815_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev-immunol-032712-095956","volume":"31","author":"NJ MacIver","year":"2013","unstructured":"MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Annu Rev Immunol. 2013;31:259\u201383. https:\/\/doi.org\/10.1146\/annurev-immunol-032712-095956.","journal-title":"Annu Rev Immunol"},{"key":"4815_CR10","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1182\/blood-2007-06-096297","volume":"111","author":"JA Wofford","year":"2008","unstructured":"Wofford JA, Wieman HL, Jacobs SR, Zhao Y, Rathmell JC. IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood. 2008;111:2101\u201311. https:\/\/doi.org\/10.1182\/blood-2007-06-096297.","journal-title":"Blood."},{"key":"4815_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.acra.2016.08.005","volume":"24","author":"JW Wachsmann","year":"2017","unstructured":"Wachsmann JW, Ganti R, Peng F. Immune-mediated disease in ipilimumab immunotherapy of melanoma with FDG PET-CT. Acad Radiol. 2017;24:111\u20135. https:\/\/doi.org\/10.1016\/j.acra.2016.08.005.","journal-title":"Acad Radiol"},{"key":"4815_CR12","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1097\/RLU.0000000000002453","volume":"44","author":"T Nobashi","year":"2019","unstructured":"Nobashi T, Baratto L, Reddy SA, Srinivas S, Toriihara A, Hatami N, et al. Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG-PET\/CT. Clin Nucl Med. 2019;44:e272\u2013e9. https:\/\/doi.org\/10.1097\/RLU.0000000000002453.","journal-title":"Clin Nucl Med"},{"key":"4815_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00259-017-3691-7","volume":"44","author":"ANM Wong","year":"2017","unstructured":"Wong ANM, McArthur GA, Hofman MS, Hicks RJ. The advantages and challenges of using FDG PET\/CT for response assessment in melanoma in the era of targeted agents and immunotherapy. Eur J Nucl Med Mol Imaging. 2017;44:67\u201377. https:\/\/doi.org\/10.1007\/s00259-017-3691-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4815_CR14","doi-asserted-by":"publisher","unstructured":"Lewin J, Sayers L, Kee D, Walpole I, Sanelli A, Te Marvelde L, et al. Surveillance imaging with FDG-PET\/CT in the post-operative follow-up of stage 3 melanoma. Ann Onc. 2018;29:1569\u201374. https:\/\/doi.org\/10.1093\/annonc\/mdy124.","DOI":"10.1093\/annonc\/mdy124"},{"key":"4815_CR15","doi-asserted-by":"publisher","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S\u201350S. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","DOI":"10.2967\/jnumed.108.057307"},{"key":"4815_CR16","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1414428.","journal-title":"N Engl J Med"},{"key":"4815_CR17","doi-asserted-by":"publisher","unstructured":"Tan AC, Emmett L, Lo S, Liu V, Kapoor R, Carlino MS, et al. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Ann Onc. 2018;29:2115\u201320. https:\/\/doi.org\/10.1093\/annonc\/mdy330.","DOI":"10.1093\/annonc\/mdy330"},{"key":"4815_CR18","doi-asserted-by":"publisher","unstructured":"Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, et al. Novel patterns of response under immunotherapy. Ann Onc. 2019;30:385\u201396. https:\/\/doi.org\/10.1093\/annonc\/mdz003.","DOI":"10.1093\/annonc\/mdz003"},{"key":"4815_CR19","doi-asserted-by":"publisher","unstructured":"Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point (18)F-FDG PET\/CT imaging in patients with advanced melanoma. J Nucl Med. 2017;58:1421\u20138. https:\/\/doi.org\/10.2967\/jnumed.116.188839.","DOI":"10.2967\/jnumed.116.188839"},{"key":"4815_CR20","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00259-018-3972-9","volume":"45","author":"C Sachpekidis","year":"2018","unstructured":"Sachpekidis C, Anwar H, Winkler J, Kopp-Schneider A, Larribere L, Haberkorn U, et al. The role of interim (18)F-FDG PET\/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging. 2018;45:1289\u201396. https:\/\/doi.org\/10.1007\/s00259-018-3972-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4815_CR21","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","volume":"45","author":"H Anwar","year":"2018","unstructured":"Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, et al. Absolute number of new lesions on (18)F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45:376\u201383. https:\/\/doi.org\/10.1007\/s00259-017-3870-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4815_CR22","doi-asserted-by":"publisher","unstructured":"Ito K, Teng R, Schoder H, Humm JL, Ni A, Michaud L, et al. (18)F-FDG PET\/CT for monitoring of Ipilimumab therapy in patients with metastatic melanoma. J Nucl Med Med. 2019;60:335\u201341. https:\/\/doi.org\/10.2967\/jnumed.118.213652.","DOI":"10.2967\/jnumed.118.213652"},{"key":"4815_CR23","doi-asserted-by":"publisher","unstructured":"Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET\/CT for assessing tumour response to immunotherapy: report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2018. https:\/\/doi.org\/10.1007\/s00259-018-4171-4.","DOI":"10.1007\/s00259-018-4171-4"},{"key":"4815_CR24","doi-asserted-by":"publisher","unstructured":"Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol.\u00a02016;34:1510\u20137. https:\/\/doi.org\/10.1200\/JCO.2015.64.0391.","DOI":"10.1200\/JCO.2015.64.0391"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04815-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-020-04815-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04815-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T12:31:03Z","timestamp":1633609863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-020-04815-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["4815"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-04815-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"26 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Professor Rodney Hicks is the recipient of a National Health and Medical Research Foundation Practitioner Fellowship (APP1108050). All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study was approved by Peter MacCallum Cancer Center Ethics Committee (approval number: 17\/231R). Authors certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Due to the retrospective nature of the study, informed consent was waived by the Peter MacCallum Cancer Center Ethics Committee (approval number: 17\/231R). Ethics committee allowed the publication of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and consent to publication"}}]}}